Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) dropped 1.1% on Wednesday . The stock traded as low as $9.57 and last traded at $9.70. 874,818 shares traded hands during trading, an increase of 159% from the average daily volume of 337,931 shares. The stock had previously closed at $9.81.
Silverback Therapeutics Trading Up 2.1%
The stock has a market capitalization of $356.97 million, a PE ratio of -4.09 and a beta of 0.60. The stock has a 50 day moving average price of $8.50 and a 200-day moving average price of $9.33.
About Silverback Therapeutics
Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.
Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.
Featured Articles
- Five stocks we like better than Silverback Therapeutics
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
- Why Palantir’s Google Cloud Deal Could Change the Debate
- AI’s Power Problem Is Turning Nuclear Stocks Into a Bigger Market Story
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
